Effect of Acarbose, an Alpha-Glucosidase Inhibitor, on Serum Lipoprotein Lipase Mass Levels and Common Carotid Artery Intima-Media Thickness in Type 2 Diabetes Mellitus Treated by Sulfonylurea

DOI Web Site PubMed 被引用文献5件 参考文献56件 オープンアクセス
  • Oyama Tomokazu
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.
  • Saiki Atsuhito
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.
  • Endoh Kei
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.
  • Ban Noriko
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.
  • Nagayama Daizi
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.
  • Ohhira Masahiro
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.
  • Koide Nobukiyo
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.
  • Miyashita Yoh
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.
  • Shirai Kohji
    Department of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University.

この論文をさがす

説明

Aim: Previous reports indicate that serum lipoprotein lipase mass levels (LPL mass) and common carotid artery intima-media thickness (CCA-IMT) are independent predictors of atherosclerotic diseases. The aim of this study was to examine the effects of combination therapy of sulfonylurea and acarbose on LPL mass and CCA-IMT.<BR>Methods: Eighty-four patients with type 2 diabetes mellitus, who were treated with only sulfonylureas and showed CCA-IMT of more than 0.9 mm at baseline, were selected and randomly divided into two groups. One group was administered acarbose 300 mg/day for 12 months (acarbose group, n=41), and the other group was not administered acarbose (non-acarbose group, n=43).<BR>Results: After 12 months, a significant increase in LPL mass and a significant decrease in CCA-IMT were observed in the acarbose group (1.024 to 0.964 mm), but no significant changes were observed in the non-acarbose group. In a subgroup analysis of patients with HbA1c improved by 0.5% or more, the increase of LPL mass and decrease of CCA-IMT was significantly greater in the acarbose group than in the non-acarbose group although the changes in HbA1c were similar in two groups.<BR>Conclusions: We concluded that reducing postprandial hyperglycemia might increase LPL mass levels and might be useful to prevent macroangiopathy in type 2 diabetic patients treated by sulfonylurea.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (56)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ